A Phase 4 interventional study of fluticasone propionate/salmeterol and fluticasone propionate in Asthma, sponsored by GlaxoSmithKline. Terminated at 1 site in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2016-12-28.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 128th largest by enrollment of the 146 interventional ones that give a count, is one of 18 that started in 2007, is one of 52 in phase 4, and was the 39th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 18 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 212th largest by enrollment of the 238 interventional ones that give a count, is one of 20 that started in 2007, is one of 53 in phase 4, and was the 56th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum, and blood draws. Subjects will inhale an FDA approved virus through their nose which is known to cause the common cold. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: fluticasone propionate/salmeterol
Drug: fluticasone propionate
Drug: placebo
Drug pages: Fluticasone · Salmeterol Xinafoate
comparator
Also known as: fluticasone propionate
Comparator
Placebo
Change From Baseline in the Cumulative Lower Respiratory Symptom Score Averaged Over Days 1-4
The cumulative lower respiratory symptom score consisted of the summary of individual scores assessing cough, shortness of breath, chest discomfort, and wheezing based on the following scale: 0 (not present); 1=mild, clearly present; 2=moderately severe, uncomfortable; 3=severe (best possible score of 12; worst possible score of 0), interfering with sleep or activity. Due to the small sample size, efficacy measures were not analyzed.
Time frame: Days 1 through 4
Change From Baseline in the Morning Peak Expiratory Flow (PEF) Averaged Over Days 1-4
PEF measurements were collected via a study-issued electronic peak flow meter. Due to the small sample size, efficacy measures were not analyzed.
Time frame: Days 1 through 4
Change From Baseline in the Morning Forced Expiratory Volume in One Second (FEV1) Averaged Over Days 1-4
FEV1 measurements were collected via a study-issued spirometer. Due to the small sample size, efficacy measures were not analyzed.
Time frame: Days 1 through 4
Change From Baseline in Exhaled Nitric Oxide (eNO) Averaged Over Days 1-4
eNO was measured using a study-issued monitor. Due to the small sample size, efficacy measures were not analyzed.
Time frame: Days 1 through 4
| Milestone | FSC 250/50 mcg BID | FP 250 mcg BID | Placebo Diskus BID |
|---|---|---|---|
| Started | 5 | 5 | 6 |
| Completed | 4 | 3 | 3 |
| Not completed | 1 | 2 | 3 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 | 1 |
The cumulative lower respiratory symptom score consisted of the summary of individual scores assessing cough, shortness of breath, chest discomfort, and wheezing based on the following scale: 0 (not present); 1=mild, clearly present; 2=moderately severe, uncomfortable; 3=severe (best possible score of 12; worst possible score of 0), interfering with sleep or activity. Due to the small sample size, efficacy measures were not analyzed.
No measurements were reported for this outcome.
PEF measurements were collected via a study-issued electronic peak flow meter. Due to the small sample size, efficacy measures were not analyzed.
No measurements were reported for this outcome.
FEV1 measurements were collected via a study-issued spirometer. Due to the small sample size, efficacy measures were not analyzed.
No measurements were reported for this outcome.
eNO was measured using a study-issued monitor. Due to the small sample size, efficacy measures were not analyzed.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FSC 250/50 mcg BID | — | 0/5 (0%) | 2/5 (40%) |
| FP 250 mcg BID | — | 0/5 (0%) | 1/5 (20%) |
| Placebo Diskus BID | — | 0/6 (0%) | 0/6 (0%) |
| Event | FSC 250/50 mcg BID | FP 250 mcg BID | Placebo Diskus BID |
|---|---|---|---|
| HeartburnGastrointestinal disorders | 1/5 | 0/5 | 0/6 |
| DiarrheaGastrointestinal disorders | 1/5 | 0/5 | 0/6 |
| InfluenzaInfections and infestations | 0/5 | 1/5 | 0/6 |
| Age, Continuous(years) | FSC 250/50 mcg BID | FP 250 mcg BID | Placebo Diskus BID | Total |
|---|---|---|---|---|
| Mean | 20.4 ± 2.07 | 20.0 ± 1.00 | 23.0 ± 5.83 | 21.25 ± 3.8 |
| Gender(Participants) | FSC 250/50 mcg BID | FP 250 mcg BID | Placebo Diskus BID | Total |
|---|---|---|---|---|
| Female | 0 | 2 | 3 | 5 |
| Male | 5 | 3 | 3 | 11 |
| Race/Ethnicity, Customized(participants) | FSC 250/50 mcg BID | FP 250 mcg BID | Placebo Diskus BID | Total |
|---|---|---|---|---|
| White | 5 | 2 | 4 | 11 |
| African American/African Heritage | 0 | 2 | 0 | 2 |
| American Indian/Alaskan Native/Native Hawaiian/Pac | 0 | 0 | 1 | 1 |
| Asian | 0 | 1 | 1 | 2 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Oct 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate